July 01, 2026

Medical Oddities: Do Jellyfish Hold a Healing Secret?

Jellyfish, pets, watermelon, brain implants, and fennel fuel this week's surprises.

Conexiant

June 23, 2026

Can Consumer Wearables Support PASC Monitoring?

Heart rate monitoring and atrial fibrillation detection had the strongest supporting evidence, but investigators found limited evidence for broader outpatient self-monitoring applications.

Conexiant

June 16, 2026

ACP Suggests First-Line Obesity Drugs

Semaglutide and tirzepatide had the greatest net benefit among evaluated treatments, the committee concluded.

Conexiant

June 11, 2026

When Bad Data Enters the Drug Pipeline

Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.

Conexiant

June 11, 2026

Medical Oddities: The Economics of Shut-Eye

Sleep became a commodity, tea became a therapy, and cats got a reprieve this week.

Conexiant

June 05, 2026

Sleep Study Cutoffs May Guide Discharge

Preoperative sleep study values may distinguish lower-risk children within a population for whom overnight admission is currently routine.

Conexiant

June 04, 2026

WHtR May Aid OSA Risk Screening

A US population analysis and a Chinese sleep-center cohort found that waist-to-height ratio was associated with obstructive sleep apnea risk, but stronger performance compared with body mass index was limited to clinically referred patients.

Conexiant

June 04, 2026

Side Effects: The Body Keeps Score

Turns out biology tracks more than we thought — from a spit test that reads your all-nighter to a surgical outcome that still shows up in household chores two decades later. Plus: habits aren't built gradually. They snap.

Conexiant

May 28, 2026

Top 10 States With Rising Demand for Physicians

These 10 states report physician shortages, projected physician supply gaps, or physician-to-population ratios below national benchmarks.

Conexiant

May 27, 2026

GLP-1 Drugs Tied to Lower Addiction Risk

In a target-trial emulation of more than 600,000 veterans, GLP-1 RA initiators saw fewer new substance use disorders—and patients with existing SUDs had fewer overdoses, hospitalizations, and deaths.

Conexiant